𝛼SK or Searchbullish
Imugene Ltd - Off-the-shelf CAR-T
SUMMARY
- Imugene Ltd (ASX:IMU) is a clinical-stage immuno-oncology company that has transitioned from a wide-ranging (expensive) pipeline into a highly-focused, late-stage execution vehicle focused on CAR-T.
- It is currently developing its platform azer-cel, an allogeneic ‘off-the-shelf’ CD19 CAR-T cell therapy for blood cancers.
- It cannot be stressed enough how different IMU is now compared with even last year – the company has made a strategic pivot towards disciplined capital management with a singular focus on its highly-prospective allogeneic CAR-T therapy.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Imugene Ltd - Off-the-shelf CAR-T11 May 2026
x